MXPA01004225A - Agente para el tratamiento del patobolismo de huesos. - Google Patents
Agente para el tratamiento del patobolismo de huesos.Info
- Publication number
- MXPA01004225A MXPA01004225A MXPA01004225A MXPA01004225A MXPA01004225A MX PA01004225 A MXPA01004225 A MX PA01004225A MX PA01004225 A MXPA01004225 A MX PA01004225A MX PA01004225 A MXPA01004225 A MX PA01004225A MX PA01004225 A MXPA01004225 A MX PA01004225A
- Authority
- MX
- Mexico
- Prior art keywords
- fioc
- administration
- polysaccharide
- human
- level
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 26
- 230000002503 metabolic effect Effects 0.000 title abstract 3
- 150000004676 glycans Chemical class 0.000 claims abstract description 48
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 48
- 239000005017 polysaccharide Substances 0.000 claims abstract description 48
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920000669 heparin Polymers 0.000 claims abstract description 18
- 229960002897 heparin Drugs 0.000 claims abstract description 18
- 235000010987 pectin Nutrition 0.000 claims description 19
- 229920001277 pectin Polymers 0.000 claims description 19
- 239000001814 pectin Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000007170 pathology Effects 0.000 claims description 17
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 10
- 208000037147 Hypercalcaemia Diseases 0.000 abstract description 9
- 230000000148 hypercalcaemia Effects 0.000 abstract description 9
- 208000030915 hypercalcemia disease Diseases 0.000 abstract description 9
- 208000001132 Osteoporosis Diseases 0.000 abstract description 5
- 102000008108 Osteoprotegerin Human genes 0.000 abstract description 4
- 108010035042 Osteoprotegerin Proteins 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 42
- 210000002966 serum Anatomy 0.000 description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 21
- 239000011575 calcium Substances 0.000 description 21
- 229910052791 calcium Inorganic materials 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 230000001184 hypocalcaemic effect Effects 0.000 description 14
- 239000012488 sample solution Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000002688 persistence Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000000539 dimer Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004279 orbit Anatomy 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- 229960002086 dextran Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000009194 citrus pectin Substances 0.000 description 4
- 229940040387 citrus pectin Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- -1 hyaluronic acid Chemical class 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 101100126626 Drosophila melanogaster Itpr gene Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32287498 | 1998-10-28 | ||
| PCT/JP1999/005963 WO2000024416A1 (fr) | 1998-10-28 | 1999-10-28 | Agents therapeutiques pour deformations osseuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01004225A true MXPA01004225A (es) | 2002-06-04 |
Family
ID=18148585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01004225A MXPA01004225A (es) | 1998-10-28 | 1999-10-28 | Agente para el tratamiento del patobolismo de huesos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6919312B2 (xx) |
| EP (1) | EP1127578A4 (xx) |
| JP (1) | JP3860415B2 (xx) |
| KR (1) | KR20010082272A (xx) |
| CN (1) | CN1183961C (xx) |
| AU (1) | AU755422B2 (xx) |
| BR (1) | BR9914834A (xx) |
| CA (1) | CA2347107A1 (xx) |
| CZ (1) | CZ20011378A3 (xx) |
| HK (1) | HK1042847A1 (xx) |
| HU (1) | HUP0104126A3 (xx) |
| IL (1) | IL142557A0 (xx) |
| MX (1) | MXPA01004225A (xx) |
| NO (1) | NO20012106L (xx) |
| NZ (1) | NZ511506A (xx) |
| PL (1) | PL347559A1 (xx) |
| RU (1) | RU2223782C2 (xx) |
| TR (1) | TR200101146T2 (xx) |
| TW (1) | TW529954B (xx) |
| WO (1) | WO2000024416A1 (xx) |
| ZA (1) | ZA200103296B (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| IL158152A0 (en) * | 2001-04-03 | 2004-03-28 | Nestle Sa | Osteoprotegerin in milk |
| CZ20022231A3 (cs) * | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) * | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
| AU2003242265A1 (en) * | 2002-06-07 | 2003-12-22 | Sankyo Company, Limited | Combined effects of therapeutic or preventive agent composition for bone breakage |
| CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
| TW200820980A (en) * | 2006-10-02 | 2008-05-16 | Nat Inst For Materials Science | A sustained-release preparation having osteoconductive activity |
| WO2008077257A1 (en) * | 2006-12-22 | 2008-07-03 | Mathys Ag Bettlach | Precursor for the preparation of a pasty bone replacement material by admixture of a liquid |
| SG181615A1 (en) * | 2009-12-09 | 2012-07-30 | Agency Science Tech & Res | Glycosaminoglycan mixtures |
| CN113088487B (zh) * | 2020-04-30 | 2022-12-06 | 威海见生生物技术有限公司 | 一种间充质干细胞成脂转化抑制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2604135B2 (ja) * | 1986-02-28 | 1997-04-30 | ライオン株式会社 | 口腔骨疾患治療剤 |
| IL91438A (en) * | 1989-08-25 | 1995-03-30 | Bukh Meditec | Preparation for treating dental disease |
| TW318142B (xx) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US20030207827A1 (en) | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| EP0911342B2 (en) | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Novel protein and process for producing the same |
| US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| KR100547395B1 (ko) | 1997-09-24 | 2006-02-01 | 산쿄 가부시키가이샤 | 골대사이상증의 진단방법 |
| DE69904818T2 (de) | 1998-06-15 | 2003-10-09 | Takeda Chemical Industries, Ltd. | Thienodipyridinderivate, ihre herstellung und verwendung |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| AU6788900A (en) * | 1999-09-03 | 2001-04-10 | Amgen, Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| CA2394536A1 (en) | 1999-12-16 | 2001-06-21 | Amgen Inc. | Tnfr/opg-like molecules and uses thereof |
| CZ20022231A3 (cs) | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
-
1999
- 1999-10-28 TR TR2001/01146T patent/TR200101146T2/xx unknown
- 1999-10-28 CZ CZ20011378A patent/CZ20011378A3/cs unknown
- 1999-10-28 AU AU64877/99A patent/AU755422B2/en not_active Ceased
- 1999-10-28 JP JP2000578024A patent/JP3860415B2/ja not_active Expired - Fee Related
- 1999-10-28 EP EP99952793A patent/EP1127578A4/en not_active Withdrawn
- 1999-10-28 WO PCT/JP1999/005963 patent/WO2000024416A1/ja not_active Application Discontinuation
- 1999-10-28 TW TW088118658A patent/TW529954B/zh not_active IP Right Cessation
- 1999-10-28 IL IL14255799A patent/IL142557A0/xx unknown
- 1999-10-28 RU RU2001114216/15A patent/RU2223782C2/ru not_active IP Right Cessation
- 1999-10-28 HU HU0104126A patent/HUP0104126A3/hu unknown
- 1999-10-28 MX MXPA01004225A patent/MXPA01004225A/es unknown
- 1999-10-28 KR KR1020017005365A patent/KR20010082272A/ko not_active Application Discontinuation
- 1999-10-28 CA CA002347107A patent/CA2347107A1/en not_active Abandoned
- 1999-10-28 PL PL99347559A patent/PL347559A1/xx not_active Application Discontinuation
- 1999-10-28 BR BR9914834-0A patent/BR9914834A/pt not_active IP Right Cessation
- 1999-10-28 NZ NZ511506A patent/NZ511506A/xx unknown
- 1999-10-28 CN CNB998128287A patent/CN1183961C/zh not_active Expired - Fee Related
-
2001
- 2001-04-12 US US09/834,008 patent/US6919312B2/en not_active Expired - Fee Related
- 2001-04-23 ZA ZA200103296A patent/ZA200103296B/en unknown
- 2001-04-27 NO NO20012106A patent/NO20012106L/no unknown
-
2002
- 2002-06-05 HK HK02104289.0A patent/HK1042847A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1042847A1 (zh) | 2002-08-30 |
| PL347559A1 (en) | 2002-04-08 |
| JP3860415B2 (ja) | 2006-12-20 |
| WO2000024416A1 (fr) | 2000-05-04 |
| HUP0104126A3 (en) | 2004-07-28 |
| TW529954B (en) | 2003-05-01 |
| ZA200103296B (en) | 2001-10-25 |
| US20010031725A1 (en) | 2001-10-18 |
| RU2223782C2 (ru) | 2004-02-20 |
| AU755422B2 (en) | 2002-12-12 |
| IL142557A0 (en) | 2002-03-10 |
| US6919312B2 (en) | 2005-07-19 |
| NO20012106L (no) | 2001-06-21 |
| EP1127578A4 (en) | 2004-12-15 |
| AU6487799A (en) | 2000-05-15 |
| CN1325310A (zh) | 2001-12-05 |
| CZ20011378A3 (cs) | 2001-10-17 |
| NO20012106D0 (no) | 2001-04-27 |
| TR200101146T2 (tr) | 2001-09-21 |
| EP1127578A1 (en) | 2001-08-29 |
| KR20010082272A (ko) | 2001-08-29 |
| BR9914834A (pt) | 2001-08-14 |
| NZ511506A (en) | 2004-02-27 |
| HUP0104126A2 (hu) | 2002-03-28 |
| CA2347107A1 (en) | 2000-05-04 |
| CN1183961C (zh) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2365000T3 (es) | Nuevas composiciones químicamente modificadas de proteína que estimulan eritropoyetina y métodos. | |
| ES2405994T5 (es) | Soluciones estabilizadas de teriparatide | |
| EP1017413B2 (de) | Flüssige interferon-beta-formulierungen | |
| MXPA01004225A (es) | Agente para el tratamiento del patobolismo de huesos. | |
| KR20150006059A (ko) | 섬유모세포 성장 인자 21 변이체 | |
| JPS6232A (ja) | 慢性関節リウマチ性貧血治療剤 | |
| PT914144E (pt) | Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana | |
| IT8224915A1 (it) | Uso di peptidi come medicamenti | |
| PT2047857E (pt) | Agente para fins de injecção compreendendo um antibióitco, e solução para injecção compreendendo o agente | |
| NL8203314A (nl) | Farmaceutische preparaten, die menselijk insuline en menselijk pro-insuline bevatten. | |
| CN102292100A (zh) | 用于治疗肺疾病的脂联素 | |
| BR0208596A (pt) | Variante de polipeptìdeo com gama interferon (ifng), seqência de nucleotìdeos, vetor de expressão, célula hospedeira de glicosilação, população de variantes de polipeptìdeo com ifng ou de uma composição, composição farmacêutica, uso de uma variante de polipeptìdeo, e, métodos para o tratamento de doenças pulmonares intersticiais, para aumentar o grau de n-glicosilação in vivo de um polipeptìdeo com ifng parental, e para a produção de uma variante de polipeptìdeo com ifng | |
| PT1299541E (pt) | Processo para obtenção e utilização de novas defensinas humanas como proteínas biologicamente activas para o tratamento de infecções e outras doenças | |
| CZ20022231A3 (cs) | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu | |
| PT1365788E (pt) | Análogos da trombomodulina para utilização na recuperação de lesão da medula espinal | |
| JP2714728B2 (ja) | 腸粘膜萎縮抑制剤 | |
| NZ546912A (en) | Use of C-peptides in manufacture of a medicament in once daily dose for treating diabetes and microvascular complications | |
| US7306791B2 (en) | Agent for preventing and/or treating multiple organ failure | |
| JPH10330285A (ja) | 血糖降下剤 | |
| JP2005281302A (ja) | 修飾インターロイキン−１１及びそれを含有する医薬組成物 | |
| JPH08231416A (ja) | 血栓症治療剤 | |
| JP3806945B2 (ja) | ヒト由来アンチトロンビン−ｉｉｉの新規用途 | |
| JPH0827026A (ja) | 肝疾患の予防・治療薬 | |
| JP3487561B2 (ja) | 顆粒球コロニー刺激因子誘導体 | |
| NL8203313A (nl) | Farmaceutische preparaten, die menselijk insuline, menselijk c-peptide en menselijk pro-insuline bevatten. |